Archives bluebird-bio

by in
Entry Author Date Location
Celgene To Pay $1B For A Big Piece of Juno and T Cell Therapies 06/29/15 Seattle
West Coast Biotech Roundup: Bock, Celladon, Arivale, Conkwest & More 06/26/15 San Diego
East Coast Biotech Roundup: Flagship, SQZ, Epizyme, IPOs & More 06/26/15 Boston
East Coast Biotech Roundup: Emulate, Pulmatrix, Synergy & More 06/19/15 New York
East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More 06/12/15 Boston
Celgene, Bluebird Streamline CAR-T Partnership To Fight Myeloma 06/03/15 Boston
East Coast Biotech Roundup: Seres, Editas, PureTech, Pronutria & More 05/29/15 Boston
Bluebird Adds to CAR-T Arsenal With Five Prime Antibody Deal 05/26/15 Boston
East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More 05/22/15 Boston
So Far, So Good in Bluebird’s First Glimpse of Sickle Cell Data 05/21/15 Boston
Bluebird, Regulators Map Out Approval Plan For Gene Therapy 05/19/15 Boston
Celgene, Versant Shake Again, Cut $30M Deal For Toronto Biotech 04/29/15 New York
Semma Secures $44M to Develop Diabetes Stem Cell Therapy 03/24/15 Boston
Epizyme Buys Back Control of Cancer Drug From Eisai For up to $110M 03/12/15 Boston
Bellicum CEO Reflects on Rise From Baylor to Houston Biotech Darling 02/26/15 Texas
Genzyme Buys into Neuro Gene Therapies With $845M Voyager Pact 02/11/15 Boston
East Coast Biotech Roundup: Hamburg, Merck, Annovation, WaVe & More 02/09/15 Boston
Now Playing: California’s $1 Billion Stem-Cell Renovation Show 02/03/15 National
Biogen Places Gene Therapy Bet in Crowded Hemophilia Space 01/29/15 Boston
J.P. Morgan 2015: Notes, Thoughts, And Conversations From the Vortex 01/16/15 National
14 for ’14: Xconomy’s Top Innovation Stories of the Year 12/29/14 National
East Coast Biotech Roundup: Yumanity, Padlock, CAR-T Fever, & More 12/19/14 Boston
Houston’s Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO 12/18/14 Texas
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind” 12/02/14 National
Juno, Less Than a Year Old, Lines up IPO to Fund Cancer Work 11/17/14 Seattle
Try Then Buy? Sutro Deal Could Be Celgene’s Biggest Antibody Bet Yet 10/23/14 New York
East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More 10/16/14 Boston
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
ARCH Venture Exploits IPO Window To Raise $400M Fund, Its Eighth 08/27/14 Seattle
Page 1 of 3 next page »